GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Renalytix Plc
Renalytix uses AI to diagnose kidney disease at an early stage. Its stock price is a bet that its diagnostic tests will become standard in medicine. The chart reflects the long road to commercialization and insurance coverage.
Share prices of companies in the market segment - Pharma kidney
Renalytix is a diagnostics company that uses artificial intelligence to predict the risk and progression of chronic kidney disease. We've categorized it under "Pharma: Kidney." The chart below shows how the market views the use of AI in medical diagnostics.
Broad Market Index - GURU.Markets
Renalytix is a diagnostics company that uses artificial intelligence to predict the risk and progression of chronic kidney disease. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Renalytix's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
RNLX - Daily change in the company's share price Renalytix Plc
Renalytix Plc's daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the stock's sensitivity to news about the implementation of its AI diagnostics for kidney disease.
Daily change in the price of a set of shares in a market segment - Pharma kidney
Renalytix develops AI-powered diagnostic tests for kidney disease risk assessment. The medical diagnostics sector is both innovative and competitive. The chart below illustrates the volatility in this niche, reflecting the high potential and risks associated with RNLX's developments.
Daily change in the price of a broad market stock, index - GURU.Markets
Renalytix uses artificial intelligence for early diagnosis of kidney disease. This medtech company's stock reflects the growing role of AI in medicine. Its volatility is part of the dynamics of the innovation sector, which influences the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Renalytix Plc
Renalytix plc's year-over-year performance is a story about the commercialization of its KidneyIntelX diagnostic test. Its market capitalization growth over the past 12 months reflects its success in securing insurance coverage and convincing doctors that its AI-based test can accurately predict the risk of developing chronic kidney disease in diabetics.
Annual dynamics of market capitalization of the market segment - Pharma kidney
Renalytix is a company using AI for the early diagnosis of kidney disease. Its innovative approach has the potential to change the standard of care. The chart below shows how its struggle to gain widespread testing and insurance coverage is impacting its performance in the medical diagnostics sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Renalytix, with its AI-powered kidney disease diagnostics, is trying to change the way chronic diseases are treated. Its performance relative to the market is a bet that healthcare systems will adopt its technology for early risk detection. Success in this area will allow it to grow faster than the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Renalytix Plc
Renalytix is a company using AI to diagnose kidney diseases. Its monthly performance reflects progress in the commercialization of its KidneyIntelX tests. News of insurance company approvals for reimbursement are key.
Monthly dynamics of market capitalization of the market segment - Pharma kidney
Renalytix is an artificial intelligence company that has developed a diagnostic platform for predicting and managing chronic kidney disease. The graph below shows the overall trend in the pharmaceutical and diagnostics sector, where AI is being used for early detection and prevention.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Stocks of companies using AI for medical diagnostics are a bet on the future. The chart below shows the overall risk appetite. Is Renalytix Plc moving in sync with the growth market, or is its success in commercializing tests creating its own trend?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Renalytix Plc
Shares of Renalytix, a company using AI to diagnose kidney diseases, reflect the future of medicine every week. Their price movements reflect the introduction of their tests into the healthcare system and data demonstrating their ability to predict the development of kidney failure.
Weekly dynamics of market capitalization of the market segment - Pharma kidney
Renalytix uses AI to diagnose and predict kidney disease. This chart compares its weekly performance with the medtech sector and helps understand how the market views its innovative approach to early disease detection, which could change treatment standards.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Renalytix uses AI to diagnose kidney diseases. The stocks of such disruptive companies often move independently of the market. This chart will help us understand: is Renalytix living in its own world of clinical trials, or is the overall market environment influencing its stock price?
Market capitalization of the company, segment and market as a whole
RNLX - Market capitalization of the company Renalytix Plc
Renalytix's market capitalization chart tells the story of a company developing AI-based diagnostic tests for the early detection of kidney disease. Its decline reflects its long road to insurance reimbursement and widespread clinical adoption. Its dynamics reflect the market's assessment of its potential to change the standard of care.
RNLX - Share of the company's market capitalization Renalytix Plc within the market segment - Pharma kidney
Renalytix uses artificial intelligence to diagnose kidney diseases. Its market capitalization in the medical diagnostics sector reflects the potential of its innovative approach. The chart below shows how the company's valuation changes as its tests become commercialized and adopted by the medical community.
Market capitalization of the market segment - Pharma kidney
Renalytix is a company using AI to diagnose and predict kidney disease. The chart below shows the market capitalization of the medical diagnostics sector. Its growth reflects the potential of predictive medicine to reduce costs and improve treatment outcomes for chronic diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Renalytix uses AI for early diagnosis of kidney disease. Its capitalization is a bet that predictive diagnostics can transform the treatment of chronic diseases. Its performance on the overall chart reflects how artificial intelligence is coming to medical laboratories to predict the future.
Book value capitalization of the company, segment and market as a whole
RNLX - Book value capitalization of the company Renalytix Plc
Renalytix's foundation is its capital and its AI-based diagnostic platform (KidneyIntelX) for the early detection and management of chronic kidney disease. This is the real, scientific, and digital foundation for preventive medicine. How has this innovative diagnostic asset evolved? The chart below shows its dynamics.
RNLX - Share of the company's book capitalization Renalytix Plc within the market segment - Pharma kidney
Renalytix uses AI to diagnose kidney diseases, which requires certified laboratories to analyze samples. The chart shows the share of these tangible assets, reflecting the physical foundation on which its diagnostic platform is built.
Market segment balance sheet capitalization - Pharma kidney
Renalytix, a kidney disease diagnostics company, has a moderately capital-intensive business. This requires the ownership of certified laboratories. The BCap_Seg chart for the medical equipment sector shows that accurate diagnostics require a substantial financial base.
Book value of all companies included in the broad market index - GURU.Markets
Renalytix's capital comes not from its clinics, but from its AI-powered diagnostic platform, KidneyIntelX, which predicts the risk of developing chronic kidney disease. The company's assets are its algorithms, patents, and laboratories. The chart below shows how this "diagnostic" biotech stacks up in terms of assets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Renalytix Plc
Renalytix uses AI to diagnose kidney disease at an early stage. Its balance sheet is based on its algorithms and laboratory capacity. Its market capitalization reflects the bet that its technology will become a standard in medicine. The chart shows the premium for innovations that could save the healthcare system billions.
Market to book capitalization ratio in a market segment - Pharma kidney
Renalytix Plc develops AI-based diagnostic tests for the early detection and management of chronic kidney disease. Its high valuation reflects the enormous potential of its technology for personalized medicine and reduced healthcare costs.
Market to book capitalization ratio for the market as a whole
Renalytix Plc develops AI-based diagnostic tests for kidney diseases. The company's value lies in its algorithms and data. This chart shows the premium investors are willing to pay for the application of artificial intelligence in medicine compared to the market average.
Debts of the company, segment and market as a whole
RNLX - Company debts Renalytix Plc
Renalytix, a company developing AI-based diagnostic tests to predict kidney disease, is using capital to conduct clinical trials and commercialize the technology. This chart shows how the company is funding its efforts to introduce a new diagnostic approach into clinical practice, which requires significant investment.
Market segment debts - Pharma kidney
Renalytix is a company developing artificial intelligence-based kidney disease diagnostics. Commercializing new diagnostic tests requires significant investment. This chart shows how the company is funding its efforts to bring its technology into clinical practice and how much it relies on external capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Renalytix Plc
Renalytix Plc develops AI-based diagnostic tests for the detection and treatment of chronic kidney diseases. This chart shows the company's reliance on debt to conduct clinical trials and commercialize its innovative tests. It is an indicator of its financial risk.
Market segment debt to market segment book capitalization - Pharma kidney
Renalytix uses artificial intelligence to develop diagnostic tests that enable the early detection of kidney disease. This is a critical task in medicine. The chart shows how the biotech sector uses debt for R&D, providing context for how Renalytix finances its capital-intensive developments.
Debt to book value of all companies in the market
Renalytix Plc uses artificial intelligence to diagnose kidney diseases, requiring investment in technology and clinical validation. This chart shows the overall debt burden in the market. It allows one to assess how a digital diagnostics company finances its innovations and how its asset-light model differs from traditional medicine.
P/E of the company, segment and market as a whole
P/E - Renalytix Plc
Renalytix Plc develops AI-based diagnostic tests for detecting and monitoring chronic kidney disease. This chart shows how the market views its predictive analytics. The trend reflects the belief that early risk detection can improve treatment outcomes and reduce healthcare costs.
P/E of the market segment - Pharma kidney
Kidney disease diagnostics, Renalytix's specialty, is an emerging field. This chart shows the average score for medical technology companies. It helps to understand that Renalytix, with its AI-powered tests, is being evaluated based on its potential to predict the risk of kidney disease, which could change treatment approaches.
P/E of the market as a whole
Renalytix is a company that uses AI to develop diagnostic tests for predicting the risk of kidney disease. Its valuation is a bet on its technology. It's not tied to general economic cycles, but depends on its ability to demonstrate that its tests improve treatment outcomes and save the healthcare system money.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Renalytix Plc
This chart for Renalytix Plc, a company developing AI-based diagnostic tests for kidney diseases, reflects market expectations for the future adoption of its products. It demonstrates analysts' belief that its tests will help doctors detect and treat chronic kidney disease earlier.
%20P%2FE%20Renalytix%20Plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Renalytix-Plc&v=1772694625107 "Chart of the company's future (projected) P/E Renalytix Plc")
Future (projected) P/E of the market segment - Pharma kidney
Renalytix is an artificial intelligence company focused on kidney disease diagnostics. Its flagship product, KidneyIntelX, is designed to predict the risk of diabetic kidney disease progression. The chart shows forecasts for the medical diagnostics sector, helping to assess the market's confidence in Renalytix's ability to transform the standard of care for patients with diabetes.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-kidney&v=1772694625114 "Future (projected) P/E graph of the market segment - Pharma kidney")
Future (projected) P/E of the market as a whole
Renalytix Plc is a company developing AI-based diagnostic tests for the prediction and treatment of kidney diseases. This is an important area of personalized medicine. This market sentiment chart influences how investors evaluate companies whose technologies can improve treatment outcomes and reduce costs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772694625124 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Renalytix Plc
Renalytix Plc is a diagnostics company that has developed an AI-powered platform (KidneyIntelX) for assessing kidney disease risk. Revenue depends on the adoption of its tests in clinical practice. This chart illustrates the complex path to commercialization of an innovative diagnostic tool in a conservative medical environment.
Profit of companies in the market segment - Pharma kidney
Renalytix Plc is an artificial intelligence company that developed the KidneyIntelX diagnostic test for assessing the risk of developing chronic kidney disease. This graph, which shows the sector's profitability, demonstrates how AI is changing medicine. Their test helps doctors identify high-risk patients and initiate treatment early to slow the disease's progression.
Overall market profit
Renalytix Plc has developed an AI-based diagnostic platform for kidney disease risk assessment. The goal is early diagnosis and personalized treatment. The company's success depends on the implementation of its tests in clinical practice. Overall economic stability, as reflected in the chart, is essential for the healthcare system to afford such innovations.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Renalytix Plc
Renalytix Plc has developed the KidneyIntelX AI-powered diagnostic platform, which helps predict the risk of developing chronic kidney disease in diabetics. This graph reflects analysts' expectations for the clinical implementation of this test, which could change treatment approaches for millions of patients.
%20profit%20of%20the%20company%20Renalytix%20Plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Renalytix-Plc&v=1772694625366 "Graph of future (projected) profit of the company Renalytix Plc")
Future (predicted) profit of companies in the market segment - Pharma kidney
Renalytix Plc is a healthcare artificial intelligence company that developed the KidneyIntelX diagnostic test for assessing the risk of developing chronic kidney disease. Growth depends on the adoption of its test in clinical practice. This chart for the medical diagnostics sector reflects expectations for the growth of personalized medicine and the demand for predictive tests.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-kidney&v=1772694625404 "Graph of future (predicted) profits of companies in a market segment - Pharma kidney")
Future (predicted) profit of the market as a whole
Renalytix develops AI-powered diagnostic tools for kidney diseases. Its success depends on the implementation of medical innovations. The overall profit forecast shown in the graph influences healthcare budgets and the willingness to pay for preventative technologies that can reduce long-term costs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772694625421 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Renalytix Plc
Renalytix is a company focused on diagnostics and developing treatment solutions for chronic kidney disease. The chart shows a high valuation for each dollar of its revenue. This reflects investors' belief that its AI-powered tests will help identify risks early and improve patient outcomes.
P/S market segment - Pharma kidney
Renalytix Plc develops AI-powered diagnostic tools for the prediction and management of chronic kidney disease. The company's revenue will depend on the adoption of its tests in clinical practice. This chart reflects the average valuation in the sector, helping to understand how investors view the potential of Renalytix's technology to improve patient outcomes.
P/S of the market as a whole
Renalytix is an artificial intelligence and diagnostics company that developed the KidneyIntelX test to assess the risk of developing chronic kidney disease. This chart, showing the average market revenue estimate, helps us understand the premium investors are willing to pay for diagnostic tools that can predict and prevent the development of serious diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Renalytix Plc
Renalytix is a diagnostics company specializing in the development of AI-powered tests for the early detection and management of chronic kidney disease. Its goal is to improve outcomes and reduce costs. This chart reflects investor expectations for the future clinical adoption of its KidneyIntelX test.
%20P%2FS%20Renalytix%20Plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Renalytix-Plc&v=1772694625525 "The graph of the company's future (projected) P/S Renalytix Plc")
Future (projected) P/S of the market segment - Pharma kidney
Renalytix Plc is a company developing AI-based diagnostic solutions for risk assessment, prognosis, and monitoring of kidney diseases. This chart shows the average estimated future sales in the medical diagnostics sector. It helps understand how the market perceives the potential of Renalytix's KidneyIntelX to improve patient care.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-kidney&v=1772694625557 "Future (projected) P/S market segment graph - Pharma kidney")
Future (projected) P/S of the market as a whole
Renalytix Plc has developed an AI-powered diagnostic platform for assessing the risk of developing chronic kidney disease. This graph reflects overall market revenue expectations. The company's technology aims to early detect and prevent disease progression, which could significantly reduce healthcare costs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772694625649 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Renalytix Plc
This chart shows the revenue of Renalytix, a company specializing in kidney disease diagnostics. Its revenue is generated from sales of the KidneyIntelX test, which helps predict the risk of kidney failure. The trend shows how rapidly this innovative diagnostic is being adopted into clinical practice.
Sales of companies in the market segment - Pharma kidney
Renalytix Plc provides AI-based diagnostic solutions for risk assessment and prognosis of chronic kidney disease. This chart illustrates the growth of the predictive diagnostics market. KidneyIntelX's technology has the potential to revolutionize treatment approaches, enabling physicians to intervene early and slow the progression of the disease.
Overall market sales
Renalytix Plc develops AI-based diagnostic tests for kidney disease. Its commercial success depends on the implementation of these tests in clinical practice. The overall economic situation, shown in this chart, affects healthcare system budgets for preventive care.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Renalytix Plc
Renalytix uses artificial intelligence to develop diagnostic tests for the early detection and management of chronic kidney disease. Future revenue depends on the implementation of its tests in clinical practice. The chart shows the AI diagnostics market forecast.
%20sales%20of%20the%20company%20Renalytix%20Plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Renalytix-Plc&v=1772694625923 "Schedule of future (projected) sales of the company Renalytix Plc")
Future (projected) sales of companies in the market segment - Pharma kidney
Renalytix is an artificial intelligence company that developed the KidneyIntelX diagnostic test to assess the risk of developing and progressing chronic kidney disease. This graph shows the forecast for the entire pharmaceutical and diagnostic market, where early kidney disease diagnosis, like Renalytix's, can save lives and reduce costs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-kidney&v=1772694625967 "Schedule of future (projected) sales of companies in the market segment - Pharma kidney")
Future (projected) sales of the market as a whole
Renalytix is an artificial intelligence company specializing in kidney disease diagnostics. Their flagship test helps identify risks at early stages. This graph, reflecting overall healthcare costs, influences the willingness of insurers and physicians to implement new diagnostic tools aimed at prevention.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772694626014 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Renalytix Plc
Renalytix develops AI-based diagnostic tests for the prognosis and treatment of chronic kidney disease. The company's profitability depends on the adoption of its tests in clinical practice. This chart shows the R&D and commercialization costs required to convince physicians and insurers of the value of a new diagnostic tool.
Market segment marginality - Pharma kidney
Renalytix is an artificial intelligence company that developed the KidneyIntelX diagnostic tool for predicting the risk of chronic kidney disease progression. Profitability depends on the clinical adoption of their test and insurance reimbursement. This chart shows the financial results of their efforts to commercialize predictive diagnostics.
Market marginality as a whole
Renalytix is a diagnostics company that has developed an AI-based test to assess the risk of chronic kidney disease in diabetic patients. This overall profitability curve isn't important to them. Their success depends on the acceptance of their test by doctors and insurance companies as a tool for early intervention and complication prevention.
Employees in the company, segment and market as a whole
Number of employees in the company Renalytix Plc
Renalytix uses artificial intelligence to diagnose kidney diseases at an early stage. Its team consists of scientists, data scientists, and laboratory technicians. The growth in this chart reflects investments in the development of its diagnostic platform and its commercialization.
Share of the company's employees Renalytix Plc within the market segment - Pharma kidney
Renalytix uses artificial intelligence to develop diagnostic tests aimed at the early detection and management of chronic kidney disease. This chart reflects its research-intensive nature. It shows the size of the team of scientists and data scientists who created and are now advancing this innovative test, which has the potential to transform the treatment of kidney disease.
Number of employees in the market segment - Pharma kidney
Renalytix Plc is an artificial intelligence company focused on kidney disease diagnostics and prognosis. This chart shows employment trends at the intersection of medicine and IT. The growth in data and bioinformatics specialists reflects advances in the development of diagnostic tools that help identify chronic kidney disease risks early and personalize treatment.
Number of employees in the market as a whole
Renalytix Plc develops AI-based diagnostic tests for the prediction and treatment of kidney diseases. The adoption of its products depends on the adoption of innovations by the healthcare system. The overall economic growth seen in this graph encourages investment in preventive medicine aimed at reducing long-term costs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Renalytix Plc (RNLX)
Renalytix Plc develops AI-powered diagnostic solutions (the KidneyIntelX platform) for the prediction and treatment of chronic kidney disease. It combines AI and biotechnology. The chart shows that the market primarily values their algorithms and database. The high market capitalization per employee reflects the company's scalability as an IT business, rather than a traditional laboratory requiring extensive staff for manual analysis.
%20of%20the%20company%20Renalytix%20Plc%20(RNLX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Renalytix-Plc-RNLX&v=1772694626230 "Chart of market capitalization per employee (in thousands of dollars) of the company Renalytix Plc (RNLX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma kidney
Renalytix is a company developing AI-based diagnostic tests for the prognosis and treatment of chronic kidney disease. Its value lies in its unique algorithms and clinical data. This chart demonstrates the market's high valuation of its intellectual property and its potential to transform treatment approaches.
%20by%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-kidney&v=1772694626242 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma kidney")
Market capitalization per employee (in thousands of dollars) for the overall market
Renalytix Plc develops AI-powered diagnostic tests for the prediction and treatment of chronic kidney diseases. The chart illustrates the valuation in the personalized medicine sector. The high cost per employee reflects the value of their predictive technology, which has the potential to save lives and reduce healthcare costs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772694626245 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Renalytix Plc (RNLX)
Renalytix is a company that uses AI to diagnose kidney diseases. Their flagship test (KidneyIntelX) analyzes biomarkers and patient data to predict the risk of kidney failure. It's a diagnostics business. This chart shows their path to profitability: revenue per employee depends on how many tests insurance companies cover.
%20Chart%20Renalytix%20Plc%20(RNLX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Renalytix-Plc-RNLX&v=1772694626262 "Company Profit Per Employee (in thousands of dollars) Chart Renalytix Plc (RNLX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma kidney
Renalytix is a company developing artificial intelligence-based kidney disease diagnostics. Their flagship test, KidneyIntelX, predicts the risk of kidney failure. This laboratory business is in the commercialization stage, and this metric reflects the balance of revenue and R&D expenses.
%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-kidney&v=1772694626287 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma kidney")
Profit per employee (in thousands of dollars) for the market as a whole
Renalytix (RNLX) is a biotech company that provides AI-powered diagnostic tests (KidneyIntelX) for kidney disease prediction. This includes R&D and service. This chart shows how much demand (margin) their test has and (more importantly) how much insurance coverage it provides to offset R&D costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772694626300 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Renalytix Plc (RNLX)
Renalytix is an artificial intelligence company that developed the KidneyIntelX diagnostic test for assessing kidney disease risk. This chart demonstrates the commercial success of its product. The growth in revenue per employee indicates the test's adoption in clinical practice and contracts with major healthcare systems.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Renalytix-Plc-RNLX&v=1772694626339 "Sales chart per company employee Renalytix Plc (RNLX)")
Sales per employee in the market segment - Pharma kidney
Renalytix (RNLX) uses AI to diagnose kidney disease. Their KidneyIntelX test analyzes biomarkers and patient data to predict the risk of kidney failure. This graph shows how much revenue each employee (scientist, data scientist, salesperson) generates from sales of these tests. This measures the productivity of their AI platform.
Sales per employee for the market as a whole
Renalytix (RNLX) is a diagnostics company that developed the AI-powered KidneyIntelX test to assess the risk of chronic kidney disease in diabetics. It's a knowledge-intensive business. This chart shows how effectively the company monetizes its diagnostic services. Revenue is generated in its laboratories and sold through a network of medical representatives.
Short shares by company, segment and market as a whole
Shares shorted by company Renalytix Plc (RNLX)
Renalytix develops AI-powered diagnostic tests for the early detection of kidney disease. The bearish sentiment shown by this chart is a bet that its tests will not be accepted by the medical community or reimbursed by insurance companies, making its business model unviable.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Renalytix-Plc-RNLX&v=1772694626375 "Short Shares Chart for the Company Renalytix Plc (RNLX)")
Shares shorted by market segment - Pharma kidney
This chart shows investor skepticism toward the diagnostic technology sector. Renalytix specializes in kidney disease tests. Active shorting of the sector indicates doubts about companies' ability to secure regulatory approval, insurance reimbursement, or commercialize their tests.
Shares shorted by the overall market
Renalytix is an R&D company developing AI diagnostics for kidney diseases. This chart illustrates the overall market pessimism. Investors fear that during a crisis, insurance companies (payers) will not cover new, expensive AI tests, preferring older methods. This is "killing" the product's commercialization.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Renalytix Plc (RNLX)
Renalytix (RNLX) uses AI (the KidneyIntelX platform) to predict the risk of developing chronic kidney disease in diabetics. This is a breakthrough diagnostic. This indicator tracks how the market is assessing the adoption of their tests, showing "overheating" (above 70) on news of insurance approval or "oversold" (below 30) on slow growth.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Renalytix-Plc-RNLX&v=1772694626399 "RSI 14 indicator chart for the company's stock Renalytix Plc (RNLX)")
RSI 14 Market Segment - Pharma kidney
Renalytix is a diagnostics company focused on kidney health. Their flagship product, KidneyIntelX, is an AI-powered test that predicts the risk of severe kidney disease in diabetics. This chart reflects overall sentiment in the biotech sector, helping to gauge the overall market sentiment toward this speculative industry.
RSI 14 for the overall market
Renalytix (RNLX) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the opportunity to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RNLX (Renalytix Plc)
Renalytix (RNLX) has developed an AI-powered diagnostic test (KidneyIntelX) that predicts the risk of developing chronic kidney disease in diabetics. This chart shows the average 12-month forecast. It reflects analysts' expectations for the test's commercial adoption by physicians and, crucially, its broad coverage under Medicare.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RNLX-Renalytix-Plc&v=1772694626477 "A chart showing analyst consensus forecasts for the expected stock price. RNLX (Renalytix Plc)")
The difference between the consensus estimate and the actual stock price RNLX (Renalytix Plc)
Renalytix (RNLX) is a kidney health predictor. Their AI platform (KidneyIntelX) analyzes data to predict the risk of chronic kidney disease in diabetics. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in the implementation of this "smart" diagnostic.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RNLX-Renalytix-Plc&v=1772694626490 "A chart showing the difference between the consensus forecast and the actual stock price. RNLX (Renalytix Plc)")
Analyst consensus forecast for stock prices by market segment - Pharma kidney
Renalytix is an "AI diagnostician" for kidneys. The company uses AI (the KidneyIntelX platform) to predict the risk of diabetic kidney disease. This chart displays analysts' overall expectations for the *entire* kidney pharma sector. It shows whether experts believe the predictive AI diagnostics market will grow.
Analysts' consensus forecast for the overall market share price
Renalytix (RNLX) – "AI" for kidneys. They developed a diagnostic test (KidneyIntelX) that uses AI to predict the risk of chronic kidney disease in diabetics. This chart shows the overall risk appetite, reflecting the willingness of investors to fund R&D companies trying to introduce new AI tests into medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Renalytix Plc
Renalytix is an AI-based kidney diagnostic tool. Their signature feature is a test (KidneyIntelX) that combines biomarkers (blood) with AI (an algorithm) to predict the risk (at an early stage) of chronic kidney disease (CKD) in diabetics. This chart summarizes their implementation history and reflects their (slow) path to Medicare reimbursement.
AKIMA Market Segment Index - Pharma kidney
Renalytix (RNLX) is an AI company for kidney pharma. They don't treat, they predict: their diagnostic test (KidneyIntelX) analyzes blood and predicts the risk of kidney failure. This chart compares their composite index to the sector, showing how their AI diagnostics outperform the competition.
The AKIM Index for the overall market
Renalytix is a diagnostic company that uses AI (KidneyIntelX) to assess the risk of kidney disease progression. This chart, reflecting the market average, is the backdrop. It helps to assess how this precision medicine struggle for insurance coverage compares to overall macroeconomic trends.
